Eton Pharmaceuticals, Inc.

ETON

Eton Pharmaceuticals, Inc.

ETON

Insider Sentiment (TTM):

Last Purchase:2025-06-10Last Sale:2026-06-17Shares Purchased (TTM):0Shares Sold (TTM):189,679

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:17,184,081Shares Outstanding:27,285,236Institutional Ownership Pct.:62.98%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Cash And Cash Equivalents At Carrying Value	27	20	26	37	25	17	15	20	18	17	21	22
Accounts Receivable Net Current	25	13	12	13	14	16	5	6	5	4	3	3
Assets Current
Assets Current	69	53	61	72	68	50	41	30	25	24	27	27
Inventory Net	10	14	15	17	24	14	15	2	2	2	1	1
Prepaid Expense And Other Assets Current	7	6	7	5	5	3	5	2	1	1	1	1
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets Net Excluding Goodwill	46	44	31	32	33	34	35	6	6	6	5	4
Operating Lease Right Of Use Asset	1	0	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	116	98	92	105	102	84	76	36	32	31	32	32
Accounts Payable Current	14	13	11	14	12	5	4	3	2	2	2	2
Long Term Debt Current	-	-	9	-	-	-	0	4	5	5	5	2
Liabilities Current
Liabilities Current	45	44	38	44	39	25	20	20	18	15	16	10
Other Accrued Liabilities Current	-	-	-	-	-	-	-	5	-	-	-	-
Debt Current	9	12	-	3	3	-	-	-	-	-	-	-
Accrued Liabilities Current	11	8	9	9	7	8	9	-	11	8	5	7
Long Term Debt	-	-	-	-	-	30	30	-	-	-	0	4
Long Term Debt Noncurrent	19	19	22	28	27	-	30	-	-	-	-	-
Operating Lease Liability Noncurrent	1	0	0	0	0	0	0	0	0	0	0	0
Accounts Payable And Accrued Liabilities Noncurren…	-	-	-	5	7	-	-	-	-	-	-	-
Other Liabilities Noncurrent	4	4	5	4	4	4	2	-	-	-	0	-
Liabilities	69	67	66	81	78	60	52	20	18	15	16	15
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	146	142	139	137	136	134	132	123	121	120	120	119
Stockholders Equity
Stockholders Equity	47	31	26	23	24	24	24	16	13	15	15	17
Retained Earnings Accumulated Deficit	-99	-111	-112	-114	-112	-109	-108	-107	-108	-105	-104	-102
Liabilities And Stockholders Equity	116	98	92	105	102	84	76	36	32	31	32	32
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	50	50	50	50	50	50	50	50	50	50	50	50
Common Stock Shares Issued	28	27	27	27	27	27	27	26	26	26	26	26
Shares Outstanding	28	27	27	27	27	27	27	26	26	26	26	26

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.77%	25.17%	63.65%	-	-	-	-	-	-	-	-	-
2025	-1.35%	-15.35%	-17.22%	13.43%	39.38%	20.97%	-15.62%	-12.07%	-21.68%	26.91%	42.75%	40.25%
2024	3.20%	-4.36%	4.07%	27.07%	60.22%	124.03%	39.59%	41.77%	92.80%	-15.19%	14.37%	14.71%
2023	-	-	-	-	-	-	-18.32%	-3.31%	0.66%	-19.51%	-16.82%	-20.40%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.52	1.21	1.57	1.63	1.77	1.97	2.06	1.51	1.40	1.59	1.65	2.61
Quick Ratio	1.15	0.75	0.98	1.14	1.03	1.33	1.02	1.31	1.24	1.37	1.53	2.46
Working Capital	23.48M	9.07M	22.09M	27.82M	29.85M	24.61M	21.07M	10.02M	7.22M	8.96M	10.60M	16.76M
Leverage & Debt
Debt to Equity	1.49	2.19	2.52	3.52	3.24	2.44	2.12	1.24	1.36	0.99	1.05	0.87
Interest Coverage TTM	6.50	0.82	-0.32	-1.01	-0.39	-2.08	-36.58	-73.51	-66.77	3.27	-4.24	6.63
Debt Ratio	0.60	0.69	0.72	0.78	0.76	0.71	0.68	0.55	0.58	0.50	0.51	0.46
Efficiency & Turnover
Asset Turnover TTM	0.97	0.96	0.95	1.00	0.87	0.84	0.72	1.03	1.00	1.25	1.11	1.24
Days Sales Outstanding TTM	67.99	62.58	39.07	48.46	60.62	77.94	41.04	47.82	46.27	37.85	30.36	27.76
Receivables Turnover TTM	5.37	5.83	9.34	7.53	6.02	4.68	8.89	7.63	7.89	9.64	12.02	13.15
Per Share Metrics
Diluted EPS TTM	0.39	-0.05	-	-0.25	-0.15	-0.17	-	-0.21	-0.26	0.04	-	0.09
Free Cash Flow Per Share TTM	0.34	0.57	0.38	0.70	0.38	0.21	0.04	0.05	-0.03	0.20	0.24	0.36
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	57.87%	54.77%	53.46%	51.36%	59.41%	58.49%	60.01%	59.30%	59.48%	66.24%	66.56%	72.47%
Operating Profit Margin TTM	15.44%	2.35%	-1.06%	-3.81%	-1.39%	-4.69%	-6.66%	-15.05%	-20.00%	1.58%	-3.77%	5.68%
Net Profit Margin TTM	12.02%	-1.70%	-5.75%	-9.50%	-7.10%	-9.49%	-9.80%	-15.81%	-21.31%	2.66%	-2.96%	6.80%
Growth Metrics
Net Revenue Growth (1Y)	81.49%	79.89%	104.94%	102.77%	85.40%	40.88%	23.29%	5.64%	8.14%	40.71%	48.90%	74.19%
Net Income Growth (1Y)	-407.36%	-67.82%	20.35%	21.91%	-38.27%	-602.08%	308.44%	-345.56%	2,757.69%	-114.38%	-89.62%	-125.10%
EPS Growth (1Y)	-399.04%	-68.29%	15.82%	17.41%	-40.83%	-581.12%	304.50%	-343.85%	2,737.18%	-114.24%	-89.83%	-124.75%
Valuation Metrics
P/E TTM	78.87	-456.54	-98.89	-87.46	-92.84	-76.13	-90.22	-28.35	-12.68	105.82	-120.01	48.05
P/B TTM	21.48	22.00	17.40	25.27	15.99	14.27	14.12	9.72	6.30	6.24	7.26	6.35
P/S TTM	9.48	7.75	5.69	8.31	6.59	7.22	8.84	4.48	2.70	2.82	3.55	3.27
Market Cap	1.00B	673.40M	455.01M	584.38M	383.23M	348.98M	344.92M	155.40M	84.81M	96.61M	112.33M	107.25M
Enterprise Value	1.00B	684.49M	459.63M	577.63M	388.02M	361.55M	359.80M	139.26M	71.77M	84.98M	96.32M	89.38M
Calculated Values
Free Cash Flow TTM	9.33M	15.43M	10.19M	18.92M	10.13M	5.52M	943.00K	1.33M	-747.00K	5.10M	6.04M	9.26M
Net Debt	1.06M	11.09M	4.62M	-6.75M	4.80M	12.57M	14.88M	-16.14M	-13.04M	-11.64M	-16.01M	-17.87M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-17Sale

Owner: Adams, Jennifer Mckie

Title: -

Shares: 50,000

Price/Share: $32.48

Value: $1,624,000.00

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-05-28Sale

Owner: Brynjelsen, Sean

Title: President & CEO

Shares: 120,000

Price/Share: $32.28

Value: $3,873,600.00

Shares Owned: 833,694

Relationship: Director,Officer

Ownership: Direct

2026-05-27Sale

Owner: Krempa, David

Title: Chief Business Officer

Shares: 19,679

Price/Share: $31.47

Value: $619,298.13

Shares Owned: 25,249

Relationship: Officer

Ownership: Direct

2025-08-20Sale

Owner: Gruber, James R.

Title: Chief Financial Officer

Shares: 2,631

Price/Share: $16.02

Value: $42,148.62

Shares Owned: 204,753

Relationship: Officer

Ownership: Direct

2025-06-16Sale

Owner: Krempa, David

Title: Chief Business Officer

Shares: 10,223

Price/Share: $14.73

Value: $150,584.79

Shares Owned: 612,646

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-17	Adams, Jennifer Mckie	Director	-	Direct	Sale	50,000	32.48	$1,624,000.00	0	4
2026-05-28	Brynjelsen, Sean	Director,Officer	President & CEO	Direct	Sale	120,000	32.28	$3,873,600.00	833,694	4
2026-05-27	Krempa, David	Officer	Chief Business Officer	Direct	Sale	19,679	31.47	$619,298.13	25,249	4
2025-08-20	Gruber, James R.	Officer	Chief Financial Officer	Direct	Sale	2,631	16.02	$42,148.62	204,753	4
2025-06-16	Krempa, David	Officer	Chief Business Officer	Direct	Sale	10,223	14.73	$150,584.79	612,646	4
2025-06-10	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Purchase	7,930	15.82	$125,452.60	2,770,000	4
2025-06-05	Brynjelsen, Sean	Director,Officer,TenPercentOwner	President & CEO	Direct	Sale	70,000	16.81	$1,176,700.00	2,873,513	4
2024-10-23	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Purchase	10,000	7.98	$79,800.00	2,770,000	4
2024-10-04	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Purchase	16,852	6.77	$114,088.04	2,720,000	4
2024-09-11	Opaleye, Management Inc.	TenPercentOwner	-	Indirect	Purchase	50,000	4.75	$237,500.00	2,705,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

62.98%

Inst. Shares: 17,184,081

Shares Outstanding: 27,285,236

2025-12-31

57.40%

Inst. Shares: 15,443,693

Shares Outstanding: 26,907,725

2025-09-30

63.95%

Inst. Shares: 17,197,447

Shares Outstanding: 26,893,000

2025-06-30

58.41%

Inst. Shares: 15,708,362

Shares Outstanding: 26,893,000

2025-03-31

49.87%

Inst. Shares: 13,408,068

Shares Outstanding: 26,886,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	17,184,081	27,285,236	62.98%
2025-12-31	15,443,693	26,907,725	57.40%
2025-09-30	17,197,447	26,893,000	63.95%
2025-06-30	15,708,362	26,893,000	58.41%
2025-03-31	13,408,068	26,886,000	49.87%
2024-12-31	12,667,027	25,895,086	48.92%
2024-09-30	9,287,151	25,900,000	35.86%
2024-06-30	7,980,256	25,778,000	30.96%
2024-03-31	6,960,917	25,763,337	27.02%
2023-12-31	6,964,353	25,645,366	27.16%
2023-09-30	6,759,476	25,719,000	26.28%
2023-06-30	5,948,855	25,593,000	23.24%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Eton Pharmaceuticals, Inc. (ETON) — SEC Financial Statements & Analysis

Eton Pharmaceuticals, Inc. (ETON) is a pharmaceutical preparations company, incorporated in DE. Eton Pharmaceuticals, Inc. trades on Nasdaq as: ETON. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Eton Pharmaceuticals, Inc. reported a 81.49% year-over-year revenue growth, a Gross Profit Margin of 57.87% (TTM), a Debt-to-Equity ratio of 1.49x, a Price-to-Sales (P/S) ratio of 9.48x (TTM), a Price-to-Book (P/B) ratio of 21.48x (TTM), at a market cap of $1.00B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 81.49%
Gross Profit Margin TTM: 57.87%
Debt To Equity: 1.49x
P/S TTM: 9.48x
P/B TTM: 21.48x
Market Cap: $1.00B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Eton Pharmaceuticals, Inc. in?

Eton Pharmaceuticals, Inc. (ETON) operates in the Pharmaceutical Preparations industry.

What is ETON's market cap?

Eton Pharmaceuticals, Inc. (ETON) has a market capitalization of $1.00B as of 2026-06-30.

What is ETON's P/E ratio?

Eton Pharmaceuticals, Inc. (ETON)'s trailing twelve month P/E ratio is 78.87x as of 2026-06-30.

What exchange does ETON trade on?

Eton Pharmaceuticals, Inc. (ETON) trades on the Nasdaq.

Where is Eton Pharmaceuticals, Inc. incorporated?

Eton Pharmaceuticals, Inc. is incorporated in DE.